Merck KGaA Reports EMA's Validation of MAA for Tepotinib to Treat Advanced NSCLC with METex14 Skipping Alterations
Shots:
- The MAA is based on a P-II VISION study assessing Tepotinib as monothx. in patients with advanced NSCLC of METex14 skipping alterations- prospectively assessed by liquid biopsy or tissue biopsy
- With the validation- the application is complete- and the EMA will now initiate the review procedure.
- Tepotinib is an oral MET inhibitor that inhibits the oncogenic MET receptor signaling caused by MET alteration. The FDA is reviewing the application under PR and through the Real-Time Oncology Review pilot program
Ref: PRNewswire | Image: Merck KGaA
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com